Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Dan Goldstein Biography and Net Worth

VP of Haemonetics

Dan Goldstein works as a Controller at Haemonetics, which is a Manufacturing company with an estimated 2,821 employees; and founded in 1971. They are part of the Accounting team within the Finance Department and their management level is Non-Manager. Dan graduated from University Of Michigan in 1998 and is currently based in Boston, United States.

What is Dan Goldstein's net worth?: The estimated net worth of Dan Goldstein is at least $335,481.68 as of June 13th, 2022. Mr. Goldstein owns 4,447 shares of Haemonetics stock worth more than $335,482 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Goldstein may own. Learn More about Dan Goldstein's net worth.
How do I contact Dan Goldstein?: The corporate mailing address for Mr. Goldstein and other Haemonetics executives is 125 Summer Street, Boston MA, 02110. Haemonetics can also be reached via phone at (781) 848-7100 and via email at [email protected]. Learn More on Dan Goldstein's contact information.
Has Dan Goldstein been buying or selling shares of Haemonetics?: Dan Goldstein has not been actively trading shares of Haemonetics during the past quarter. Most recently, Dan Goldstein sold 42 shares of the business's stock in a transaction on Monday, June 13th. The shares were sold at an average price of $62.60, for a transaction totalling $2,629.20. Following the completion of the sale, the vice president now directly owns 4,447 shares of the company's stock, valued at $278,382.20. Learn More on Dan Goldstein's trading history.
Who are Haemonetics' active insiders?: Haemonetics' insider roster includes Michelle Basil (EVP), William Burke (CFO), Dan Goldstein (VP), Mark Kroll (Director), Anila Lingamneni (EVP), Josep Llorens (EVP), Richard Meelia (Director), Laurie Miller (SVP), Jacqueline Scanlan (SVP), Christopher Simon (CEO, President & Director), and Stewart Strong (Insider). Learn More on Haemonetics' active insiders.
Are insiders buying or selling shares of Haemonetics?: During the last twelve months, insiders at the medical instruments supplier sold shares 9 times. They sold a total of 33,828 shares worth more than $3,031,094.99. The most recent insider tranaction occured on July, 26th when insider Stewart W Strong sold 4,312 shares worth more than $393,038.80. Insiders at Haemonetics own 1.8% of the company. Learn More about insider trades at Haemonetics.
Information on this page was last updated on 7/26/2024.

Dan Goldstein Insider Trading History at Haemonetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/13/2022	Sell	42	$62.60	$2,629.20	4,447
6/2/2022	Sell	249	$62.69	$15,609.81	4,489
5/16/2022	Sell	50	$56.10	$2,805.00	4,004
6/14/2021	Sell	39	$59.87	$2,334.93
6/7/2021	Sell	81	$55.09	$4,462.29
5/19/2021	Sell	42	$55.19	$2,317.98
5/17/2021	Sell	42	$55.97	$2,350.74
2/4/2021	Sell	2,671	$135.86	$362,882.06
10/26/2020	Sell	100	$106.00	$10,600.00
6/16/2020	Sell	4,456	$90.25	$402,154.00
6/12/2020	Sell	42	$82.29	$3,456.18
6/9/2020	Sell	1,376	$96.23	$132,412.48
5/18/2020	Sell	101	$101.72	$10,273.72
5/15/2020	Sell	42	$100.44	$4,218.48
4/8/2020	Sell	399	$97.12	$38,750.88
4/6/2020	Sell	2,607	$101.62	$264,923.34
10/28/2019	Sell	100	$120.33	$12,033.00
10/25/2019	Sell	1,456	$120.32	$175,185.92
8/9/2019	Sell	475	$133.23	$63,284.25
6/12/2019	Sell	39	$109.37	$4,265.43
6/10/2019	Sell	192	$104.38	$20,040.96
6/6/2019	Sell	1,107	$103.25	$114,297.75
4/9/2019	Sell	3,206	$88.90	$285,013.40
12/10/2018	Sell	1,693	$102.91	$174,226.63
10/26/2018	Sell	102	$101.69	$10,372.38
6/7/2018	Sell	3,794	$95.09	$360,771.46
4/6/2018	Sell	518	$54.65	$28,308.70	4,002
11/13/2017	Sell	4,691	$54.93	$257,676.63	3,747

Dan Goldstein Buying and Selling Activity at Haemonetics

Haemonetics Company Overview

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $75.44

$74.70

$77.79

50 Day Range

MA: $81.38

$71.15

$93.38

2 Week Range

Now: $75.44

$70.25

$97.97

Volume

1,502,820 shs

Average Volume

555,120 shs

Market Capitalization

$3.79 billion

P/E Ratio

31.30

Dividend Yield

N/A

Beta

0.38

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.